Genmab A/S (NASDAQ:GMAB - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $20.23, but opened at $20.93. Genmab A/S shares last traded at $20.84, with a volume of 112,594 shares.
Several research analysts have weighed in on the stock. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a "buy" rating on the stock. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $45.20.
Read Our Latest Stock Report on Genmab A/S
The business has a 50-day moving average of $21.27 and a 200-day moving average of $24.15. The company has a market capitalization of $13.78 billion, a P/E ratio of 20.21, a P/E/G ratio of 0.59 and a beta of 0.97.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. Sell-side analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.
A number of large investors have recently modified their holdings of GMAB. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. Blue Trust Inc. grew its holdings in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after acquiring an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after purchasing an additional 1,413 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC purchased a new stake in shares of Genmab A/S in the 3rd quarter worth approximately $192,000. Hedge funds and other institutional investors own 7.07% of the company's stock.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.